NCT02388490View on ClinicalTrials.gov

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 25, 2016

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Interventions
DRUG

brentuximab vedotin

Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.

Trial Locations (3)

Unknown

Seoul National University Bundang Hospital, Seongnam

Seoul National Unversity Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

lead

Seoul National University Hospital

OTHER

NCT02388490 - Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas | Biotech Hunter | Biotech Hunter